Actively Recruiting
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
80
Participants Needed
15
Research Sites
151 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D\[s\]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with multiple myeloma (MM) whose disease has come back after treatment (relapsed) or hasn't responded to treatment (refractory).
CONDITIONS
Official Title
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Diagnosis of relapsed or refractory multiple myeloma with measurable disease defined by specific levels of serum or urine M-protein or abnormal free light chain levels
- Prior treatment including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 therapy
- ECOG performance status of 0 or 1
- Estimated glomerular filtration rate (eGFR) greater than 30 mL/min/1.73 m²
- Agreement to avoid breastfeeding, pregnancy, gamete donation, and to use an external condom during treatment and for 6 months after last dose
You will not qualify if you...
- Active plasma cell leukemia, Waldenström's macroglobulinemia, POEMS syndrome, or immunoglobulin light chain amyloidosis
- Prior allogeneic transplant within 6 months or autologous transplant within 12 weeks before study treatment
- Receipt of live attenuated vaccine within 4 weeks before first dose
- CNS involvement or meningeal involvement of multiple myeloma
- Unresolved non-hematologic toxicity greater than Grade 1 from prior anticancer therapy (except alopecia, tissue fibrosis, or mild peripheral neuropathy)
- High cumulative corticosteroid dose (≥140 mg prednisone equivalent) within 14 days before treatment
- Recent antitumor therapies within specified timeframes before first dose, including targeted therapy, monoclonal antibodies, chemotherapy, and radiotherapy
- Pulmonary compromise requiring supplemental oxygen
- Active infections such as HIV with detectable viral load or low CD4 count, active hepatitis B or C, or serious uncontrolled infections
- Active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before treatment
- Certain cardiac conditions including recent myocardial infarction and severe congestive heart failure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
2
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Actively Recruiting
3
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
4
Asan Medical Center
Seoul, South Korea, 05505
Actively Recruiting
5
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
6
The Catholic University of Korea Seoul St Marys Hospital
Seoul, South Korea, 137 701
Actively Recruiting
7
Hosp. Univ. Germans Trias I Pujol
Badalona, Spain, 08916
Actively Recruiting
8
Hosp Clinic de Barcelona
Barcelona, Spain, 08036
Actively Recruiting
9
Hosp Univ Fund Jimenez Diaz
Madrid, Spain, 28040
Actively Recruiting
10
Clinica Univ. de Navarra
Pamplona, Spain, 31008
Actively Recruiting
11
Hosp Clinico Univ de Salamanca
Salamanca, Spain, 37007
Actively Recruiting
12
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan, 833
Actively Recruiting
13
China Medical University Hospital
Taichung, Taiwan, 404
Actively Recruiting
14
National Cheng Kung University Hospital
Tainan, Taiwan, 70403
Actively Recruiting
15
National Taiwan University Hospital
Taipei, Taiwan, 100225
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here